Diagnostic biomarkers in hepatocellular carcinoma

Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility

Because of the high prevalence and associated-mortality of hepatocellular carcinoma (HCC), early diagnosis of the disease is vital for patient survival. In this regard, tumor size is one of the two main prognostic factors for surgical resection, which constitutes the only curative treatment for HCC along with liver transplantation. However, techniques for HCC surveillance and diagnosis that are...

Hepatocellular Carcinoma in Sheep

Biomarkers for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Here, we review on our current understanding of HCC biomarkers.

Biomarkers for Hepatocellular Carcinoma

The hepatocellular carcinoma (HCC) is one of the most common malignant tumors and carries a poor survival rate. The management of patients at risk for developing HCC remains challenging. Increased understanding of cancer biology and technological advances have enabled identification of a multitude of pathological, genetic, and molecular events that drive hepatocarcinogenesis leading to discover...

Biomarkers in hepatocellular carcinoma--letter.

We read with great interest the study by Llovet and colleagues (1), who reported on plasma biomarkers in a phase III trial of sorafenib for advanced hepatocellular carcinoma (HCC; ref. 2). One of the main scopes of this correlative study was to identify predictive markers of survival and response to sorafenib. Within a panel of 10 candidate biomarkers that were analyzed in both the placebo and ...